PHASE-II STUDY OF LIPOSOMAL MURAMYL TRIPEPTIDE PHOSPHATIDYLETHANOLAMINE (MTP PE) IN ADVANCED SOFT-TISSUE SARCOMAS OF THE ADULT - AN EORTC SOFT-TISSUE-AND-BONE-SARCOMA-GROUP STUDY/

Authors
VERWEIJ J JUDSON I STEWARD W COLEMAN R WOOL P VANPOTTELSBERGHE C VANGLABBEKE M MOURIDSEN H
Citation
J. Verweij et al., PHASE-II STUDY OF LIPOSOMAL MURAMYL TRIPEPTIDE PHOSPHATIDYLETHANOLAMINE (MTP PE) IN ADVANCED SOFT-TISSUE SARCOMAS OF THE ADULT - AN EORTC SOFT-TISSUE-AND-BONE-SARCOMA-GROUP STUDY/, European journal of cancer, 30A(6), 1994, pp. 842-843
Citations number
13
Categorie Soggetti
Oncology
Journal title
European journal of cancer → ACNP
ISSN journal
09598049
Volume
30A
Issue
6
Year of publication
1994
Pages
842 - 843
Database
ISI
SICI code
0959-8049(1994)30A:6<842:PSOLMT>2.0.ZU;2-D
Abstract
The EORTC Soft Tissue and Bone Sarcoma Group conducted a phase II stud y with intravenous muramyl tripeptide phosphatidylethanolamine (MTP/PE ) at a dose of 4 mg once weekly in 20 patients with metastatic soft ti ssue sarcomas. Responses were not seen in 19 evaluable patients, Toxic ity consisted mainly of a mild flu-like syndrome after 62% of drug adm inistrations. It is concluded that MTP/PE at this dose and schedule ha s no activity in metastatic soft tissue sarcoma.